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Abstract  
 Bis imidazolium salts, with alkyl chain linkers ranging from methylene to dodecyl, were 
synthesized with naphthylmethyl substituents at the N1 and N1’ positions for a structure-activity 
relationship (SAR) study. All compounds were characterized by 1H and 13C NMR spectroscopy. 
The cationic portion of 2 as the PF6 salt, 3, 4, and 5 were also characterized by single-crystal X-
ray crystallography. Compounds 1-8, 10, and 12 were tested for their in vitro anti-cancer activity 
against four NSCLC cell lines via the MTT assay (NCI–H460, NCI–H1975, HCC827, and 
A549). Compounds 10 and 12 which contained the decyl and dodecyl chains, respectively, had 
IC50 values of < 1 μM (NCI-H460), < 1 μM (A549), 2 μM (NCI-H1975), and 7 μM (HCC827) 
and < 1 μM (NCI-H460), < 1 μM (A549), < 1 μM (NCI-H1975), and 4 μM (HCC827), 
respectively. The results of the MTT assays showed that activity increased as the length of the 
alkyl linker increased; the bis imidazolium salts with longer chains, compounds 6-8, 10, and 12, 
had  IC50 values comparable to cisplatin.The National Cancer Institute’s (NCI) Developmental 
Therapeutics Program (DTP) also tested compounds 1-8, 10, and 12 with its 60 human cancer 
cell line panel in the one-dose assay (10 μM). These results corroborated the SAR findings of our 
lab that activity increased with the longer chain alkyls, compounds 6-8, 10, and 12, linking the 
imidazole rings, with compound 12 being the most active having lethality against all of the 
NSCLC lines examined and lethality against nearly all cell lines tested. 
Keywords: Bis Imidazolium salt; Anti-cancer; Anti-tumor; Lung cancer; SAR study 
Abbreviations: NCI – National Cancer Institute; DTP – Developmental Therapeutics Program; 
IC50 – inhibitory concentration 50 %; NSCLC – non-small cell lung cancer; IS29 – 1,3-
bis(naphthalen-2-ylmethyl)imidazolium bromide; MTT - 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide; SAR – Structure-Activity Relationship; DNA – Deoxyribonucleic 
Acid 
 
  
Introduction 
  It is estimated that over 595,000 Americans will die of cancer in 2016, and of those 
deaths over 158,000 will be due to lung cancer; it causes more deaths in both men and women 
than any other form of cancer, and it accounts for one in four deaths due to cancer. Lung cancer 
is categorized into small and non-small cell types with the latter making up 83 % of cases.1 One 
commonly used class of chemotherapeutics for the treatment of NSCLC is cisplatin and its 
analogues which are platinum-based drugs. Severe side effects can be expected by patients 
undergoing platinum-based therapy, e.g. renal dysfunction is experienced by 20 % of patients 
treated with high doses of cisplatin. Relapse may also 
occur as cancerous cells become resistant to cisplatin.2 
The five-year survival rate for patients with lung cancer is 
only 18% which is bleak.1 New chemotherapeutics are 
needed to treat NSCLC which do not have as severe side 
effects. Imidazolium salts (Figure 1) may provide a better 
alternative. Imidazolium salts, including bis imidazolium 
salts (Figure 2), have been synthesized toward many 
ends, including as ionic liquids and ligands in transition 
metal chemistry, because of the versatility with which 
they can be substituted.3, 4 
 While investigating the anti-tumor ability of silver carbene complexes, our group found 
that the imidazolium salt precursors to silver NHC’s demonstrated high activity against NSCLC 
lines.5 A structure-activity relationship (SAR) study was conducted with some earlier 
imidazolium salts once it was discovered that imidazolium salts with naphthylmethyl groups, as 
in the case of 1,3-bis(naphthalen-
2-ylmethyl)imidazolium bromide 
(IS29; Figure 3), or similar 
hydrophobic substituents had 
increased anti-proliferative 
activity against our NSCLC lines. 
The study kept a naphthylmethyl at the N1 position and alkyl chains at the N3 position; salts had 
increased activity as the length of the alkyl chain increased. The issue with IS29 and salts with 
highly hydrophobic substituents is that they have poor water solubility which limits their utility.6 
Analogues of IS29 in the form of bis 
imidazolium salts with alkyl chain 
linkers (Figure 4) will have increased 
water solubility due to increased in the 
molecule. 
Creating this bridging system 
may also cause the analogues to have a 
different modus operandi in halting cell 
proliferation. These systems would also 
be analogous to the bis intercalating 
antibiotic echinomycin (Figure 5). 
Echinomycin is a depsipeptide with two 
quinoxaline moieties which intercalate 
double-stranded DNA. Naphthalene is a 
two-membered polycyclic aromatic hydrocarbon, much like quinoxaline, which lends to the 
notion that this series of compounds could have similar functionality to echinomycin, especially 
with the flexible alkyl chain also being analogous to the flexible peptide sequence bridging the 
quinoxaline moieties.7 
Water solubility and activity will change as the length of the alkyl chain bridging the two 
imidazole rings changes. Maholtra and Kumar found that imidazolium salts with a methyl group 
at the N1 position and alkyl chains at the N3 position had increased activity as the length of the 
alkyl chain increased. Salts with alkyl chains with seven or less carbons were not active against 
the cell lines tested.8 This agrees with the findings of the Youngs’ lab with imidazolium salts 
with a naphthylmethyl group at the N1 position and alkyl chains at the N3 position, and our 
results show that water solubility drastically declined with increasing alkyl chain. The salt with a 
naphthylmethyl substituent and an ethyl chain substituent had a solubility of 13.5 mg/mL in 
water and had IC50 values of 26 μM (NCI-H460), > 30 μM (NCI-H1975), and > 30 μM 
(HCC827) while the salt with a naphthylmethyl substituent and a nonyl chain substituent had a 
solubility of 0.3 mg/mL in water and had IC50 values of 10 μM (NCI-H460), 3 μM (NCI-H1975), 
and 3 μM (HCC827).6 Therefore, one can tune the bis imidazolium salt systems by the length of 
the alkyl chain linker to maximize activity and have sufficient water solubility. 
 
 
 
 
 
 
Results and Discussion 
Synthesis and characterization 
For compound 1 (Equation 1), a slight excess of two molar equivalences of 2-
(bromomethyl)naphthalene was added to a solution with di(imidazol-1-yl)methane. The solution 
was refluxed overnight to afford 1 as a white precipitate. 1 was recrystallized in a solution of 
water and ethanol (1:6). For compounds 2-12 (Equation 2), the appropriate dibromo alkane 
reagent was added to a solution that contained naphthylmethyl imidazole. These solutions were 
refluxed overnight to produce precipitates for compounds 2-7 and 10. 3, 4, 6, and 7 were washed 
with cold acetonitrile to remove unreacted starting materials. 2 was washed with acetone, 5 was 
recrystallized in a solution of water and ethanol (1:6), and 10 was washed in acetone and diethyl 
ether. Compounds 8, 9, 11, and 12 remained soluble even in room temperature acetonitrile. 8 was 
recrystallized in a solution of water and ethanol (1:5), 9 and 11 were dissolved in water and 
extracted with diethyl ether, the water was removed under reduced pressure, and methylene 
chloride was added to the oils to induce precipitation, and 12 was washed in acetone. 
Compounds 8 and 12 were filtered in open atmosphere, while compounds 9 and 11 were filtered 
in a glove bag with a nitrogen atmosphere. 
 All compounds were characterized by 1H and 13C NMR spectroscopy and phase transition 
temperature as none of the compounds formed a liquid at high temperatures and all the 
compounds eventually degraded. The cationic portion of 2 as the hexafluorophosphate salt and 
compounds 3, 4, and 5 were characterized by single-crystal X-ray crystallography. The evidence 
for the synthesis of compounds devoid of other organic molecules by 1H NMR was only one 
resonance detected in the aromatic region where the proton attached to the C2 carbon of the 
imidazole ring appears (9.00 < ppm < 10.00) and a downfield shift of the methylene protons 
between the imidazole ring and the naphthalene rings from 5.36 for naphthylmethyl imidazole to 
between 5.50 and 6.00 ppm. In some cases, two resonances were detected with one being much 
smaller, presumably the mono-cationic species if complete alkylation did not occur, in which 
case the product was either reacted with additional 2-(bromomethyl)naphthalene or purified via 
recrystallization. This was the case with compounds 1, 5, and 8 which were recrystallized, and 
compounds 2, 9, and 11 which were reacted with additional 2-(bromomethyl)naphthalene. 
All resonances in the 1H and 13C were accounted for, but with the 1H NMR spectra and 
the 13C NMR spectra the aromatic protons and aromatic carbons, respectively, could not feasibly 
be assigned with surety. The chemical shifts of the methylene protons in the alkyl chains 
bridging the imidazole rings decreased in ppm the further from the imidazole rings they were due 
to the deshielding effects of the rings, which was intriguing to examine with the different alkyl 
chain lengths. The chemical shifts of the carbons in the alkyl chains bridging the imidazole rings 
also decreased in ppm the further from the imidazole rings there were due to the deshielding 
effects of the aromatic imidazole rings. With the bis systems, there were some carbons that were 
equivalent due to symmetry so the integrations were viewed. An integration of 2 was observed 
for carbons which had at least one hydrogen bonded to it, but carbons that had no hydrogens did 
not have correct integrations because their relaxations were presumably too long for accurate 
integration data to be collected for them. The 1H and 13C NMR spectra collected from 
compounds 1-12 are included in Appendix 2. The 1H and 13C NMR spectra of compounds 1-8, 
10, and 12 were obtained on a Varian 500 MHz instrument, and the 1H NMR spectra of 
compounds 9 and 11 were collected on a Varian 300 MHz instrument. 
 The cationic portion of 2 as the hexafluorophosphate salt and compounds 3, 4, and 5 were 
characterized by single-crystal X-ray crystallography. The anion exchange for compound 2 was 
conducted by dissolving a sample of it in water and adding ammonium hexafluorophosphate. A 
precipitate formed, the cationic portion of compound 2 with hexafluorophosphate as the anion, 
which was collected by filtration. A single crystal was collected from the slow evaporation of the 
compound dissolved in a solution of acetonitrile, chloroform, and 2-propanol (Figure 6). The 
asymmetric unit of 2 was half of the molecule due to the crystallographically imposed mirror 
plane. The crystals of compounds 3, 4, and 5 were grown from the slow evaporation of solvent: 
compound 3 was grown from a solution of ethyl acetate and tetrahydrofuran (Figure 7), 
  
 
 
 
 compound 4 was grown from methanol (Figure 8), and compound 5 was grown from water  
(Figure 9). One molecule of 3 co-crystallized with two water molecules, the asymmetric unit of 
 4 was half of the molecule due to the crystallographically imposed mirror plane, and one 
molecule of 5 co-crystallized with one water molecule.  
In vitro efficacy studies 
 The anti-proliferative activities of compounds 1-8, 10, and 12 (Figures 8-11) were tested 
against four non-small cell lung cancer cell lines (NSCLC) (A549, NCI-H460, NCI-H1975, and 
HCC827). Cells were treated with compounds 1-8, 10, 12, and cisplatin for 72 hours. Cell  
 
 
 viability was determined by the MTT assay after this time period. The anti-proliferative effects 
of compounds 1-8, 10, and 12 were evaluated by their ability to inhibit growth by 50% compared 
to control cells (IC50 value). Solutions of each compound were prepared by dissolving the 
compound in DMSO and then diluting with water to a final concentration of 1% DMSO in water. 
The compound solutions were further diluted into growth medium with a maximum DMSO 
concentration of 0.032% added to the cells. 
Compounds 6-8, 10, and 12 (Table 1) had high activity against all cell lines, but they had 
less activity against the HCC827 cell line. Compounds 1-5 displayed less activity than the 
aforementioned compounds with compounds 1-3 having much less activity that was not 
comparable to cisplatin which had IC50 values of 4 µM (H460), 9 µM (H1975), 6 µM (HCC827),  
 and 6 µM (A549).  IS29 had IC50 values of 4 µM (H460), 3 µM (H1975), 4 µM (HCC827), and 
10 µM (A549). To compare, compound 12, which had the highest activity, had IC50 values of < 1 
µM (H460), < 1 µM (H1975), 4 µM (HCC827), and < 1 µM (A549). The results also show the 
general trend that as the length of the alkyl chain increases, the anti-proliferative activity is 
greater. It is well known that hydrophobicity aids in permeating the cell membrane so these 
results may simply be a result of this.9 These results are also consistent with that of Malhotra and 
Kumar. They found that imidazolium salts with a methyl group at the N1 position and alkyl 
chains at the N3 position had increased activity as the length of the alkyl chain did. Salts with  
alkyl chains with seven or less carbons were not active against the cell lines tested.8 These results 
agree with the SAR study of these compounds according to the IC50 values for compounds 1-8, 
10, and 12. Increasing the length of the alkyl chain bridging the two imidazole rings increases 
activity, which is the expected result of this study. 
The National Cancer Institute’s (NCI) Developmental Therapeutics Program (DTP) also 
tested 1-8, 10, and 12 in its 60 human cancer cell line screen using a one-dose assay and agreed 
NCI-H460 NCI-H1975 HCC827 A549
Cisplatin 4 9 6 6
IS29 4 3 4 10
1 16 >30 >30 >30
2 14 >30 >30 >30
3 20 >30 >30 22
4 4 11 13 4
5 2 12 >30 4
6 2 6 12 <1
7 3 3 10 2
8 2 3 15 2
10 <1 2 7 <1
12 <1 <1 4 <1
Compound
IC50 Values (μM)
Table 1. IC50 values of cisplatin, IS29, and compounds 1-8, 10, and 12 against the NSCLC 
lines NCI-H460, NCI-H1975, HCC827, and A549. 
 
to test 10 and 12 using a five-dose assay. Compounds 1-8 did not have high enough activity to be 
accepted into the five-dose study. The results from the five-dose assay for 12 have not been 
obtained. The NCI-60 human cancer cell screen contains nine NSCLC cell lines. Results from 
the one-dose assay for 1-8, 10, and 12 are summarized in Table 2. The cells are exposed to one 
concentration, 10 µM, of the compounds in the 60 cell line assay. Results were given as a growth 
percentage of cells treated with 1-8, 10, and 12 compared to growth of control cells. The growth 
percentages decreased with increasing chain length and eventually were all negative, thereby 
displaying lethality, at compound 12. This agrees with the results for IC50 values found from our 
MTT assays run with these compounds that increasing chain length leads to less proliferation. 
Compound 12 had an average lethality against the nine non-small cell lung cancer cell lines 
tested of 60.87 % which illustrates the utility of increasing the length of the bridging alkyl chain 
between the imidazole rings as part of this SAR study. 
In the five-dose assay, 10 was exposed to all 60 cell lines at concentrations of 10 nM, 100 
nM, 1 µM, 10 µM, and 100 µM. Results were given as concentrations of 50% growth inhibition 
(GI50), total growth inhibition (TGI), and 50% lethal concentration (LC50) relative to cell 
growth with no drug added and initial cell count. Results of the five-dose assay for 10 are shown 
A549/ATCC EKVX HOP-62 HOP-92 NCI-H226 NCI-H23 NCI-H322M MCI-H460 NCI-H522 Average
1 70.78 89.40 84.22 66.99 92.61 88.32 87.60 85.07 50.99 79.55
2 64.07 91.44 85.95 79.18 82.65 88.91 86.40 85.63 63.70 80.88
3 62.32 82.70 67.18 67.47 81.89 77.85 84.40 75.28 56.58 72.85
4 49.31 58.07 54.76 68.41 82.03 44.04 90.05 38.24 43.40 58.70
5 41.68 47.15 57.01 66.04 72.59 45.32 86.17 30.48 38.74 53.91
6 38.64 37.30 55.83 59.93 69.59 30.46 76.24 24.59 33.07 47.29
7 26.68 27.92 32.56 N/A 59.45 14.44 58.62 14.63 5.87 30.02
10 18.55 13.71 -4.86 -23.56 39.46 5.67 34.54 11.00 -72.29 2.47
12 -74.19 -62.61 -58.01 -68.19 -42.06 -80.31 -18.39 -69.88 -74.23 -60.87
Compound
Growth Percentage
Table 2. Growth percentage values for compounds 1-8, 10, and 12 against the NSCLC lines 
in the NCI’s DTP 1-dose 60 cell line screen. 
 
in Table 3 and Figure 14. The GI50 concentration ranges from the mid nanomolar range (376 
nm) to the low µM range (3.55 µM), the TGI concentration ranges from 1.94 µM to 18.4 µM, 
and the LC50 concentration ranges from 5.95 µM to > 100 µM. These results give further 
evidence that 10 has potent anti-proliferative activity and merits further studies. Experimental 
procedures for the one-dose and five-dose assays can be found on the DTP website. However, to  
 
 
clarify results, growth percentages in the one-dose and five-dose assays performed by the DTP 
were based on the concentration of proteins at the examined time points. Results from all other 
cell lines and figures of the tables provided by the DTP are presented in Appendix 3. 
Conclusion 
 Lipophilic imidazolium salts display anti-proliferative activity against human cancer cell 
lines. The issue with this is that they are so lipophilic that they are only sparingly soluble in 
water. The bis imidazolium salts, which are analogous to IS29, display enhanced water solubility 
when compared to IS29 itself. The water solubility drops off as the length of the alkyl chain 
Table 3. The growth inhibition 50 % (GI50), 
total growth inhibition (TGI), and lethal 
concentration 50 % concentrations for 
compound 10 against the NSCLC lines 
screened by the DTP in its 5-dose studies. 
GI50 TGI LC50
A549/ATCC N/A 1.33E-05 5.03E-05
EKVX 4.42E-07 9.07E-06 5.84E-05
HOP-62 1.09E-06 7.24E-06 4.45E-05
HOP-92 3.96E-07 2.96E-06 1.52E-05
NCI-H226 9.18E-07 1.36E-05 > 1.00E-4
NCI-H23 4.45E-07 3.35E-06 3.99E-05
NCI-H332M 3.55E-06 1.84E-05 4.81E-05
NCI-H460 3.76E-07 1.01E-05 4.59E-05
NCI-H522 4.36E-07 1.94E-06 5.95E-06
Concentration (M)
Cell Line
increases, but the anti-proliferative activity increases at the same time, with compound 12 having 
IC50 values greater than both IS29 and cisplatin. 
 The bis systems with longer chain alkyls, compounds 6-8, 10, and 12, displayed the 
greatest IC50 values as determined from via the MTT assay. These compounds were also 
accepted into the NCI’s DTP 60 cell line 1-dose screen. Both studies affirmed the SAR study 
that the activity of these compounds increases with increasing alkyl chain length. Compounds 10 
and 12 were active enough in the 60 cell line screen to be accepted into the 5-dose screen. 
Compound 10 had excellent results for the 50% growth inhibition (GI50), total growth inhibition 
(TGI), and 50% lethal concentration (LC50) against the NSCLC lines studied. This is why 
further biological studies will be conducted on the dihydro systems in order to determine 
possible cellular targets. 
The synthesis and characterization of the 4,5-dichloroimidazole analogues would be the 
logical next step in the research of bis salts to examine the activity and compare it against the 
dihydro systems. The proposed synthesis of this series of compounds is similar to the synthesis 
of compounds 2-12 (Scheme 1). These systems would also have the ability to coordinate to 
silver centers as NHC ligands for use as antibiotics (Equations 3 and 4). These compounds will 
have cytotoxicity against eukaryotic cells as well as microbes once they are coordinated to silver 
centers. This would lend these compounds to being excellent candidates for dual purpose drugs, 
such as bladder exfoliants for treatment of recurrent urinary tract infections.10 
Experimental Section 
General Procedures 
 All reactions were conducted under aerobic conditions except where indicated. 2-
(Bromomethyl)naphthalene was purchased from Waterstone Technologies. 1,2-dibromoethane 
was purchased from Baker, 1,3-dibromopropane, 1,4-dibromobutane, 1,6-dibromohexane, and 
1,8-dibromooctane were purchased from Acros Organics, 1,5-dibromopentane was purchased 
from Alfa Aesar, 1,7-dibromoheptane and 1,10-dibromodecane were purchased from TCI, 1,11-
dibromoundecane was purchased from Aldrich, and 1,12-dibromododecane was purchased from 
Avocado. Imidazole was purchased from Acros Organics. Naphthylmethyl imidazole was 
synthesized according to literature procedures.11 Di(imidazol-1-yl)methane (0.50 g, 3.4 mmol) 
was dissolved in hot chloroform and filtered to remove yellow particulates. The filtrate was 
cooled to room temperature to produce crystals of di(1H-imidazol-1-yl)methane which was 
filtered. All solvents were purchased from Fisher Scientific. All reagents were used as received 
without further purification. 1H and 13C NMR spectra were obtained on a Varian 500 MHz 
instrument with all spectra referenced to residual deuterated solvent for compounds 1-8, 10, and 
12 (DMSO-d6:  1H NMR: 2.50 ppm, 13C NMR: 39.5 ppm). 1H and 13C NMR spectra were 
obtained on a Varian 300 MHz instrument with all spectra referenced to residual deuterated 
solvent for compounds 9 and 11 (DMSO-d6:  1H NMR: 2.50 ppm, 13C NMR: 39.5 ppm). 
Single-Crystal X-ray Crystallography Procedures 
 Crystals of the compounds were coated in paratone oil, mounted on a CryoLoop and 
placed on the goniometer head under a stream of nitrogen (100 K). The data sets were collected 
on a Bruker Kappa APEX II Duo CCD system equipped with a Mo ImuS (λ = 0.71073 Å) source 
and a Cu ImuS micro-focus source equipped with QUAZAR optics (λ = 1.54178 Å). The unit 
cells were determined by using reflections from three different orientations. Data sets were 
integrated using SAINT.12 An empirical absorption correction and other corrections were applied 
to the data sets using multi-scan SADABS. Structure solution, refinement, and modeling were 
accomplished by using the Bruker SHELXTL package.13 The structures were determined by full-
matrix least-squares refinement of F2 and the selection of the appropriate atoms from the 
generated difference map. Hydrogen atom positions were calculated and Uiso(H) values were 
fixed according to a riding model. 
 The human NSCLC cell lines NCI-H1975 and HCC827 were generously provided by Dr. 
Lindner from the Cleveland Clinic. The human NSCLC cell lines NCI-H460 and NCI-A549 
were purchased from ATCC (Manassas, VA, USA). All cell lines were grown at 37 °C with 5% 
CO2 in RPMI 1640 medium supplemented with 10% fetal bovine serum and passed every 2-3 
days. 
MTT assay 
 Cells were grown to confluence and plated in 96-well plates at 5,000-7,000 cells per well, 
depending on the cell line. Cells were incubated for 24 h prior to adding the compounds. All 
compounds were dissolved in a 1% DMSO solution and diluted in fresh medium to the desired 
concentrations of 1, 4, 16, and 32 M. Compounds were added (6 replicates each) and cells were 
incubated for 72 h at which time the MTT assay protocol was followed. MTT reagent (10 L) 
was added to each well and cells were incubated for 3-4 h, again depending on the cell line. 
Growth medium was removed by aspiration and DMSO (100 L) was added to each well. Plates 
were incubated for 15 min. The optical density was read at 540 nm on a Biotek Epoch plate 
reader. 
Synthesis of 1-(naphthalen-2-ylmethyl)-3-((3-(naphthalen-2-ylmethyl)-imidazolium-1-
yl)methyl)-imidazolium bromide (1) 
 Di(1H-imidazol-1-yl)methane (0.12 g, 0.8 mmol) was dissolved in acetonitrile (7 mL) 
and 2-(bromomethyl)naphthalene (0.40 g, 1.8 mmol) was added. The reaction was heated and 
stirred at 70 °C overnight. The volatile components were removed under reduced pressure, and 
the white solid was washed with acetone (25 mL) and chloroform (15 mL), subsequently. The 
product was recrystallized in a solution of water and ethanol (1:6). After filtration, the crystals 
were ground to a fine powder by mortar and pestle and residual volatile components were 
removed under reduced pressure to purify the white solid (0.42 g, 87 % yield). Found C, 58.51; 
H, 4.28; N, 9.45%. Calculated for C29H26N4Br2: C, 59.0; H, 4.4; N, 9.5%. Phase Transition, 283 – 
285°C. 1H NMR (500 MHz, DMSO-d6) δ = 9.70 (2H, s, Ar), 8.13-7.93 (12H, m, Ar), 7.59-7.57 
(6H, m, Ar), 6.72 (2H, s, CH2), 5.68 (4H, s, CH2). 
13C NMR (125 MHz, DMSO-d6) δ = 137.8 
(NCN), 132.8 (Ar), 132.6 (Ar), 131.5 (Ar), 128.7 (Ar), 128.0 (Ar), 127.8 (Ar), 127.6 (Ar), 126.8 
(Ar), 126.7 (Ar), 125.9 (Ar), 123.3 (Ar), 122.5 (Ar), 58.3 (CH2), 52.5 (CH2). 
Synthesis of 1-(naphthalen-2-ylmethyl)-3-(2-(3-(naphthalen-2-ylmethyl)-imidazolium-1-
yl)ethyl)-imidazolium bromide (2) 
 1,2-Dibromoethane (56 μL, 0.7 mmol) and 1-(naphthalen-2-ylmethyl)-imidazole (0.30 g, 
1.4 mmol) were heated in acetonitrile (5 mL) overnight. The volatile components were removed 
under reduced pressure, and the white solid was triturated with acetone and filtered. Residual 
volatile components were removed under reduced pressure to yield a white solid (0.06 g, 16 % 
yield). Found C, 60.67; H, 4.21; N, 9.37%. Calculated for 1: C, 59.6; H, 4.7; N, 9.3%. Phase 
Transition, 285°C. 1H NMR (500 MHz, DMSO-d6) δ = 9.32 (2H, s, Ar), 7.98-7.91 (8H, m, Ar), 
7.86 (2H, dd, Ar), 7.73 (2H, dd, Ar), 7.58-7.57 (4H, m, Ar), 7.48 (1H, d, Ar), 7.46 (1H, d, Ar), 
5.57 (4H, s, CH2), 4.75 (4H, t, CH2). 
13C NMR (125 MHz, DMSO-d6) δ = 136.8 (NCN), 132.7 
(Ar), 132.6 (Ar), 131.8 (Ar), 128.7 (Ar), 127.8 (Ar), 127.63 (Ar), 127.60 (Ar), 126.8 (Ar), 126.7 
(Ar), 125.6 (Ar), 122.94 (Ar), 122.86 (Ar), 52.2 (CH2), 48.5 (CH2). 
Crystal data for 1,1'-methylenebis(3-(naphthalen-2-ylmethyl)-imidazolium) 
hexafluorophosphate(V): C30H28F12N4P2, M = 734.50, monoclinic, a = 35.130(2) Å, b = 
6.9080(4) Å, c = 12.5665(8) Å, β = 101.406(3)°, V = 2989.4(3) Å3, T = 100(2) K, space group 
C2/c, Z = 4, 11425 reflections measured, 3039 independent reflections (Rint = 0.0413). The final 
R1 values were 0.0477 (I > 2σ(I)). The final wR(F2) values were 0.1154 (I > 2σ(I)). The final R1 
values were 0.0713 (all data). The final wR(F2) values were 0.1308 (all data). 
Synthesis of 1-(naphthalen-2-ylmethyl)-3-(3-(3-(naphthalen-2-ylmethyl)-imidazolium-1-
yl)propyl)-imidazolium bromide (3) 
 1,3-Dibromopropane (66 μL, 0.7 mmol) and 1-(naphthalen-2-ylmethyl)-imidazole (0.30 
g, 1.4 mmol) were heated in acetonitrile (5 mL) overnight. The clear solution was cooled (-20 
°C) to induce precipitation. The white power was filtered and washed with cold (-20 °C) 
acetonitrile (25 mL). A fine, white powder was collected (0.34 g, 84 % yield). Found C, 55.69; 
H, 4.94; N, 8.61%. Calculated for 2: C, 60.2; H, 4.9; N, 9.1%. Phase Transition, 145 – 147°C. 1H 
NMR (500 MHz, DMSO-d6) δ = 9.49 (2H, s, Ar), 8.01-7.89 (12H, m, Ar), 7.59-7.55 (6H, m, 
Ar), 5.62 (4H, s, CH2), 4.30 (4H, t, CH2), 2.46 (2H, p, CH2). 
13C NMR (125 MHz, DMSO-d6) δ 
= 136.5 (NCN), 132.7 (Ar), 132.6 (Ar), 132.0 (Ar), 128.7 (Ar), 127.8 (Ar), 127.7 (Ar), 127.6 
(Ar), 126.7 (Ar), 126.6 (Ar), 125.8 (Ar), 122.7 (Ar), 122.6 (Ar), 52.1 (CH2), 46.0 (CH2), 29.3 
(CH2). 
Crystal data for 3: C31H30N4Br2, M = 636.42, monoclinic, a = 21.4487(8) Å, b = 
12.5771(4) Å, c = 10.6265(4) Å, β = 91.5181(17)°, V = 2865.62(18) Å3, T = 100(2) K, space 
group P21/c, Z = 4, 51189 reflections measured, 5811 independent reflections (Rint = 0.0435). 
The final R1 values were 0.0335 (I > 2σ(I)). The final wR(F2) values were 0.0784 (I > 2σ(I)). The 
final R1 values were 0.0520 (all data). The final wR(F
2) values were 0.0861 (all data). 
Synthesis of 1-(naphthalen-2-ylmethyl)-3-(4-(3-(naphthalen-2-ylmethyl)-imidazolium-1-
yl)butyl)-imidazolium bromide (4) 
 1,4-Dibromobutane (78 μL, 0.7 mmol) and 1-(naphthalen-2-ylmethyl)-imidazole (0.30 g, 
1.4 mmol) were heated in acetonitrile (5 mL) overnight. A white precipitate formed, and the 
mixture was cooled (-20 °C) to induce further precipitation. The white power was filtered and 
washed with cold (-20 °C) acetonitrile (25 mL). A fine, white powder was collected (0.32 g, 76 
% yield). Found C, 57.62; H, 5.13; N, 8.33%. Calculated for 4: C, 60.8; H, 5.1; N, 8.9%. Phase 
Transition, 223 – 225°C. 1H NMR (500 MHz, DMSO-d6) δ = 9.37 (2H, s, Ar), 7.98-7.83 (12H, 
m, Ar), 7.58-7.52 (6H, m, Ar), 5.60 (4H, s, CH2), 4.23 (4H, t, CH2), 1.81 (4H, t, CH2). 
13C NMR 
(125 MHz, DMSO-d6) δ = 136.3 (NCN), 132.68 (Ar), 132.65 (Ar), 132.1 (Ar), 128.7 (Ar), 127.8 
(Ar), 127.63 (Ar), 127.57 (Ar), 126.74 (Ar), 126.71 (Ar), 125.7 (Ar), 122.71 (Ar), 122.69 (Ar), 
52.1 (CH2), 48.2 (CH2), 26.0 (CH2). 
Crystal data for 4: C32H36N4O2Br2, M = 668.47, monoclinic, a = 11.8237(4) Å, b = 
11.7179(3) Å, c = 10.6439(3) Å, β = 99.8580(10)°, V = 1452.93(7) Å3, T = 100(2) K, space 
group P21/c, Z = 2, 15219 reflections measured, 2950 independent reflections (Rint = 0.0330). 
The final R1 values were 0.0307 (I > 2σ(I)). The final wR(F2) values were 0.0801 (I > 2σ(I)). The 
final R1 values were 0.0377 (all data). The final wR(F
2) values were 0.0849 (all data). 
Synthesis of 1-(naphthalen-2-ylmethyl)-3-(5-(3-(naphthalen-2-ylmethyl)-imidazolium-1-
yl)pentyl)-imidazolium bromide (5) 
 1,5-Dibromopentane (178 μL, 1.3 mmol) and 1-(naphthalen-2-ylmethyl)-imidazole (0.60 
g, 2.9 mmol) were heated in acetonitrile (4 mL) overnight. The volatile components were 
removed under reduced pressure, and the white solid was triturated and filtered with cold (-20 
°C) acetone (25 mL). The white powder was recrystallized in a solution of water and ethanol 
(1:6). The crystals were filtered and washed with acetone (15 mL). The volatile components 
were removed under reduced pressure to yield a white powder (0.44 g, 52 % yield). Phase 
Transition, 226 – 228°C. 1H NMR (500 MHz, DMSO-d6) δ = 9.49 (2H, s, Ar), 8.00-7.87 (12H, 
m, Ar), 7.58-7.54 (6H, m, Ar), 5.63 (4H, s, CH2), 4.21 (4H, t, CH2), 1.85 (4H, tt, CH2), 1.25 (2H, 
p, CH2). 
13C NMR (125 MHz, DMSO-d6) δ = 136.2 (NCN), 132.7 (Ar), 132.6 (Ar), 132.1 (Ar), 
128.7 (Ar), 127.8 (Ar), 127.6 (Ar), 127.6 (Ar), 126.70 (Ar), 126.67 (Ar), 125.7 (Ar), 122.7 (Ar), 
122.6 (Ar), 52.1 (CH2), 48.5 (CH2), 28.5 (CH2), 22.0 (CH2). 
Crystal data for 5: C33H36N4Br2O, M = 664.48, monoclinic, a = 10.7412(9) Å, b = 
23.605(3) Å, c = 11.5324(13) Å, β = 90.046(4)°, V = 2924.0(5) Å3, T = 100(2) K, space group 
P21/n, Z = 4, 38687 reflections measured, 5562 independent reflections (Rint = 0.0694). The final 
R1 values were 0.0334 (I > 2σ(I)). The final wR(F2) values were 0.0735 (I > 2σ(I)). The final R1 
values were 0.0467 (all data). The final wR(F2) values were 0.0786 (all data). 
Synthesis of 1-(naphthalen-2-ylmethyl)-3-(6-(3-(naphthalen-2-ylmethyl)-imidazolium-1-
yl)hexyl)-imidazolium bromide (6) 
 1,6-Dibromohexane (135 μL, 0.9 mmol) and 1-(naphthalen-2-ylmethyl)-imidazole (0.40 
g, 1.9 mmol) were heated in acetonitrile (7 mL) overnight. A white precipitate formed, and the 
reaction mixture was cooled (-20 °C) to induce further precipitation. The white precipitate was 
filtered and washed with cold (-20 °C) acetonitrile (30 mL) (0.44 g, 77 % yield). Found C, 61.62; 
H, 5.31; N, 8.42%. Calculated for 6: C, 61.8; H, 5.5; N, 8.5%. Phase Transition, 233 – 234°C. 1H 
NMR (500 MHz, DMSO-d6) δ = 9.57 (2H, s, Ar), 8.02-7.89 (12H, m, Ar), 7.59-7.54 (6H, m, 
Ar), 5.66 (4H, s, CH2), 4.20 (4H, t, CH2), 1.81 (4H, tt, CH2), 1.27 (4H, t, CH2). 
13C NMR (125 
MHz, DMSO-d6) δ = 136.2 (NCN), 132.7 (Ar), 132.6 (Ar), 132.2 (Ar), 128.7 (Ar), 127.8 (Ar), 
127.58 (Ar), 127.56 (Ar), 126.7 (Ar), 126.6 (Ar), 125.7 (Ar), 122.7 (Ar), 122.5 (Ar), 52.0 (CH2), 
48.7 (CH2), 28.9 (CH2), 24.7 (CH2). 
Synthesis of 1-(naphthalen-2-ylmethyl)-3-(7-(3-(naphthalen-2-ylmethyl)-imidazolium-1-
yl)heptyl)-imidazolium bromide (7) 
 1,7-Dibromoheptane (149 μL, 0.9 mmol) and 1-(naphthalen-2-ylmethyl)-imidazole (0.40 
g, 1.9 mmol) were heated in acetonitrile (7 mL) overnight. The clear solution was cooled (-20 
°C) and the white precipitate which formed was washed with cold (-20 °C) acetonitrile (25 mL). 
The white powder was dried via aspirator filtration (0.38 g, 64 % yield). The solubility of the 
product in deionized water is 19.5 mg/mL. Found C, 60.94; H, 5.67; N, 8.06%. Calculated for 7: 
C, 62.3; H, 5.7; N, 8.3%. Phase Transition, 198 – 200°C. 1H NMR (500 MHz, DMSO-d6) δ = 
9.53 (2H, s, Ar), 8.00-7.88 (12H, m, Ar), 7.58-7.54 (6H, m, Ar), 5.64 (4H, s, CH2), 4.19 (4H, t, 
CH2), 1.79 (4H, tt, CH2), 1.29 (2H, tt, CH2), 1.22 (2H, p, CH2). 
13C NMR (125 MHz, DMSO-d6) 
δ = 136.2 (NCN), 132.7 (Ar), 132.6 (Ar), 132.2 (Ar), 128.7 (Ar), 127.8 (Ar), 127.60 (Ar), 127.55 
(Ar), 126.7 (Ar), 126.6 (Ar), 125.6 (Ar), 122.7 (Ar), 122.6 (Ar), 52.0 (CH2), 48.8 (CH2), 29.0 
(CH2), 27.5 (CH2), 25.2 (CH2). 
Synthesis of 1-(naphthalen-2-ylmethyl)-3-(8-(3-(naphthalen-2-ylmethyl)-imidazolium-1-
yl)octyl)-imidazolium bromide (8) 
 1,8-Dibromooctane (161 μL, 0.9 mmol) and 1-(naphthalen-2-ylmethyl)-imidazole (0.40 
g, 1.9 mmol) were heated in acetonitrile (3 mL) overnight. The volatile components were 
removed via rotary evaporation under reduced pressure. The off-white powder was washed and 
filtered with cold (-20 °C) acetone (25 mL). The powder was recrystallized in an ethanol and 
water solution (5:1). The crystals were washed and filtered with cold (-20 °C) acetone (15 mL). 
The crystals were crushed to an off-white powder which was dried under reduced pressure (0.50 
g, 83 % yield). Found C, 59.58; H, 5.57; N, 7.65%. Calculated for 8: C, 62.8; H, 5.9; N, 8.1%. 
1H 
NMR (500 MHz, DMSO-d6) δ = 9.46 (2H, s, Ar), 7.99-7.86 (12H, m, Ar), 7.57-7.54 (6H, m, 
Ar), 5.63 (4H, s, CH2), 4.18 (4H, t, CH2), 1.78 (4H, tt, CH2), 1.24-1.20 (8H, m, CH2). 
13C NMR 
(125 MHz, DMSO-d6) δ = 136.2 (NCN), 132.7 (Ar), 132.6 (Ar), 132.2 (Ar), 128.7 (Ar), 127.8 
(Ar), 127.6 (Ar), 127.5 (Ar), 126.70 (Ar), 126.68 (Ar), 125.6 (Ar), 122.7 (Ar), 122.6 (Ar), 52.1 
(CH2), 48.9 (CH2), 29.1 (CH2), 28.1 (CH2), 25.3 (CH2). 
 
Synthesis of 1-(naphthalen-2-ylmethyl)-3-(9-(3-(naphthalen-2-ylmethyl)-imidazolium-1-
yl)nonyl)-imidazolium bromide (9) 
1,9-Dibromoundecane (293 μL, 1.4 mmol) and 1-(naphthalen-2-ylmethyl)-imidazole 
(0.600 g, 2.9 mmol) were heated in acetonitrile (4 mL) overnight. The volatile components from 
the reaction were removed under reduced pressure. The resulting viscous, white oil was 
dissolved in deionized water (300 mL) and extracted twice with diethyl ether (100 mL). The 
water layer was collected and the water was removed under reduced pressure. The viscous, 
transparent, and tan oil was triturated with methylene chloride (100 mL) which induced 
precipitation of a tan solid. The mixture was filtered in a glove bag with a nitrogen environment. 
The tan solid was collected and stored at ambient conditions in open atmosphere (0.522 g, 53 % 
yield). Calculated for 9: C, 63.7; H, 6.2; N, 7.8%. 
1H NMR (300 MHz, DMSO-d6) δ = 9.43 (2H, 
s, Ar), 7.98-7.84 (12H, m, Ar), 7.59-7.53 (6H, m, Ar), 5.64 (4H, s, CH2), 4.18 (4H, t, CH2), 1.78 
(4H, tt, CH2), 1.23-1.20 (10H, m, CH2). 
Synthesis of 1-(naphthalen-2-ylmethyl)-3-(10-(3-(naphthalen-2-ylmethyl)-imidazolium-1-
yl)decyl)-imidazolium bromide (10) 
 1,10-Dibromodecane (0.26 g, 0.9 mmol) and 1-(naphthalen-2-ylmethyl)-imidazole (0.40 
g, 1.9 mmol) were heated in acetonitrile (3 mL) overnight. The reaction mixture was cooled (-20 
°C) because a white precipitate formed at room temperature. The chilled mixture was filtered and 
the white solid was washed with acetone (25 mL). The white solid was subsequently washed 
with diethyl ether (25 mL) three times. The white solid was dried under reduced pressure (0.31 g, 
49 % yield). Found C, 62.88; H, 6.26; N, 7.61%. Calculated for 10: C, 63.7; H, 6.2; N, 7.8%. 
Phase Transition, 66°C. 1H NMR (500 MHz, DMSO-d6) δ = 9.43 (2H, s, Ar), 7.99-7.85 (12H, m, 
Ar), 7.59-7.53 (6H, m, Ar), 5.62 (4H, s, CH2), 4.18 (4H, t, CH2), 1.78 (4H, tt, CH2), 1.22-1.20 
(12H, m, CH2). 
13C NMR (125 MHz, DMSO-d6) δ = 136.2 (NCN), 132.7 (Ar), 132.6 (Ar), 132.2 
(Ar), 128.7 (Ar), 127.8 (Ar), 127.60 (Ar), 127.55 (Ar), 126.7 (Ar), 126.6 (Ar), 125.6 (Ar), 122.7 
(Ar), 122.6 (Ar), 52.0 (CH2), 48.8 (CH2), 29.0 (CH2), 27.5 (CH2), 25.2 (CH2). 
Synthesis of 1-(naphthalen-2-ylmethyl)-3-(11-(3-(naphthalen-2-ylmethyl)-imidazolium-1-
yl)undecyl)-imidazolium bromide (11) 
1,11-Dibromoundecane (340 μL, 1.4 mmol) and 1-(naphthalen-2-ylmethyl)-imidazole 
(0.601 g, 2.9 mmol) were heated in acetonitrile (4 mL) overnight. The volatile components from 
the reaction were removed under reduced pressure. The resulting viscous, white oil was 
dissolved in deionized water (300 mL) and extracted twice with diethyl ether (100 mL). The 
water layer was collected and the water was removed under reduced pressure. The viscous, clear 
oil was triturated with methylene chloride (100 mL) which induced precipitation of a white solid. 
The mixture was filtered in a glove bag with a nitrogen environment. The solid was taken out of 
the bag which caused it to phase transition to a clear oil again. The oil was dissolved in 
chloroform (40 mL) and evaporated at ambient conditions in open atmosphere. A white, 
crystalline solid was collected (0.182 g, 18 % yield). Calculated for 11: C, 64.1; H, 6.4; N, 7.7%. 
1H NMR (300 MHz, DMSO-d6) δ = 9.41 (2H, s, Ar), 7.99-7.87 (12H, m, Ar), 7.58-7.53 (6H, m, 
Ar), 5.63 (4H, s, CH2), 4.18 (4H, t, CH2), 1.78 (4H, tt, CH2), 1.23-1.19 (14H, m, CH2).  
Synthesis of 1-(naphthalen-2-ylmethyl)-3-(12-(3-(naphthalen-2-ylmethyl)-imidazolium-1-
yl)dodecyl)-imidazolium bromide (12) 
 1,12-Dibromododdecane (0.29 g, 0.9 mmol) and 1-(naphthalen-2-ylmethyl)-imidazole 
(0.40 g, 1.9 mmol) were heated in acetonitrile (3 mL) overnight. The volatile components were 
removed under reduced pressure and the off-white solid which formed was washed with acetone 
(25 mL). The solid became a highly-viscous gel on the filter paper. After a week of being 
undisturbed in a fume hood, the hardened, tan product was ground and collected (0.31 g, 48 % 
yield). The solubility of the product in deionized water is 2.6 mg/mL. Found C, 63.83; H, 6.45; 
N, 7.40%. Calculated for 12: C, 64.5; H, 6.5; N, 7.5%. Phase Transition, 137 – 138°C. 1H NMR 
(500 MHz, DMSO-d6) δ = 9.46 (2H, s, Ar), 7.98-7.86 (12H, m, Ar), 7.58-7.54 (6H, m, Ar), 5.63 
(4H, s, CH2), 4.19 (4H, t, CH2), 1.79 (4H, tt, CH2), 1.23-1.19 (12H, m, CH2). 
13C NMR (125 
MHz, DMSO-d6) δ = 136.2 (NCN), 132.7 (Ar), 132.6 (Ar), 132.2 (Ar), 128.7 (Ar), 127.8 (Ar), 
127.6 (Ar), 127.5 (Ar), 126.68 (Ar), 126.65 (Ar), 125.6 (Ar), 122.7 (Ar), 122.6 (Ar), 52.0 (CH2), 
48.9 (CH2), 29.2 (CH2), 28.8 (CH2), 28.3 (CH2), 25.5 (CH2). 
Supporting Information. Safety consideration of this project, the 1H and 13C NMR for 
compounds 1-12, and the NCI 1- and 5-dose data sheets are included in the supporting 
information as Appendices 1, 2, and 3, respectively. 
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Appendix 1: Safety Considerations 
 There were various, serious safety considerations that were taken into account as this 
project progressed. A basic precaution was that gloves and safety glasses were worn at all times 
in the lab to prevent exposure to various chemicals in the lab. When using a base bath to clean 
glassware, a lab coat and acid gloves were worn to prevent exposure to the alcoholic hydroxide 
solution when placing items into or taking items out of the base bath. In a few instances, aqua 
regia was used to clean NMR tubes and other pieces of glassware that the base bath did not 
clean. A lab coat and acid gloves were worn when preparing aqua regia solutions, and the 
solutions were always carefully prepared in a fume hood with sodium bicarbonate spread around 
the container holding the solution. Aqua regia was neutralized with sodium bicarbonate to a 
neutral pH, and the resulting solution was disposed of in an aqueous waste container. 
 The greatest safety hazard were the chemicals utilized in the synthesis of these 
compounds and the compounds themselves. The brominated reagents, the dibromo alkyl reagents 
and 2-(bromomethyl)naphthalene, are carcinogenic irritants. Care was taken to not be exposed to 
fumes from the reagent containers, and the reagents were carefully transferred to the analytical 
balance and from the balance to the reaction flasks. The most dangerous chemicals were the 
products themselves because the results obtained from the MTT assays and from the NCI results 
show that they are highly cytotoxic. Similar imidazolium salts synthesized by this group were 
found to be fatal to mice at a concentration of 30 mg/kg body weight. An average adult male 
weights 70 kg, so it would take roughly 2 g of the more toxic compounds to kill someone. This 
shows that even slight inhalation over time of these compounds is extremely hazardous. This was 
a real concern because many of the compounds formed fine powders with a great deal of 
electrostatic interactions which made transferring them to vials rather difficult. The products had 
to be transferred using a spatula in most cases, and even then they stuck to the weigh paper and 
had a tendency to become airborne in small amounts. This is why these transfers were completed 
in a fume hood with the sash down as far as possible while still allowing mobility of arms inside 
of it. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 2: 1H and 13C NMR Spectra 
 
Figure A2.1. 1H NMR spectrum of 1. 
 
Figure A2.2. 13C NMR spectrum of 1. 
 Figure A2.3. 1H NMR spectrum of 2. 
 
Figure A2.4. 13C NMR spectrum of 2. 
 
 Figure A2.5. 1H NMR spectrum of 3. 
 
Figure A2.6. 13C NMR spectrum of 3. 
 Figure A2.7. 1H NMR spectrum of 4. 
 
Figure A2.8. 13C NMR spectrum of 4. 
 Figure A2.9. 1H NMR spectrum of 5. 
 
Figure A2.10. 13C NMR spectrum of 5. 
 Figure A2.11. 1H NMR spectrum of 6. 
 
Figure A2.12. 13C NMR spectrum of 6. 
 Figure A2.13. 1H NMR spectrum of 7. 
 
Figure A2.14. 13C NMR spectrum of 7. 
 Figure A2.15. 1H NMR spectrum of 8. 
 
Figure A2.16. 13C NMR spectrum of 8. 
 Figure A2.17. 1H NMR spectrum of 9. 
 
Figure A2.18. 1H NMR spectrum of 10. 
 Figure A2.19. 13C NMR spectrum of 10. 
 
Figure A2.20. 1H NMR spectrum of 11. 
 Figure A2.21. 1H NMR spectrum of 12. 
 
Figure A2.22. 13C NMR spectrum of 12. 
 
 
 
 
 
 
 
Appendix 3: NCI 60 Cell Line Screen Data 
 
Figure A3.1. 60 cell line screen 1-dose assay for 1. 
 Figure A3.2. 60 cell line screen 1-dose assay for 2. 
 Figure A3.3. 60 cell line screen 1-dose assay for 3. 
 Figure A3.4. 60 cell line screen 1-dose assay for 4. 
 Figure A3.5. 60 cell line screen 1-dose assay for 5. 
 Figure A3.6. 60 cell line screen 1-dose assay for 6. 
 Figure A3.7. 60 cell line screen 1-dose assay for 7. 
 Figure A3.8. 60 cell line screen 1-dose assay for 10. 
 Figure A3.9. 60 cell line screen 5-dose assay dose response curves for 10. 
 ‘Figure A3.10. 60 cell line screen 5-dose assay in-vitro testing results for 10. 
 ‘Figure A3.11. 60 cell line screen 5-dose assay mean graphs for 10. 
 Figure A3.12. 60 cell line screen 5-dose assay dose response curves for all cell lines for 10. 
 Figure A3.13. 60 cell line screen 1-dose assay for 12. 
